Selected research
Market Structure
Global Age Related Macular Degeneration Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Age Related Macular Degeneration Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Age Related Macular Degeneration Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Age Related Macular Degeneration Drugs include Novartis, Roche, Bayer Healthcare, Regeneron Pharmaceuticals, Neurotech Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Age Related Macular Degeneration Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Age Related Macular Degeneration Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Age Related Macular Degeneration Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Age Related Macular Degeneration Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Age Related Macular Degeneration Drugs Segment by Company
Novartis
Roche
Bayer Healthcare
Regeneron Pharmaceuticals
Neurotech Pharmaceuticals
Allergan
Age Related Macular Degeneration Drugs Segment by Type
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Lucentis
Others
Age Related Macular Degeneration Drugs Segment by Application
50-60 Years Old
60-70 Years Old
Others
Age Related Macular Degeneration Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Age Related Macular Degeneration Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age Related Macular Degeneration Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Age Related Macular Degeneration Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Age Related Macular Degeneration Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Eylea
- Avastin
- Squalamine
- Conercept
- Lampalizamab
- Lucentis
- Others
Applications
- 50-60 Years Old
- 60-70 Years Old
- Others
Companies covered
- Novartis
- Roche
- Bayer Healthcare
- Regeneron Pharmaceuticals
- Neurotech Pharmaceuticals
- Allergan
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Age Related Macular Degeneration Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Age Related Macular Degeneration Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Age Related Macular Degeneration Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Age Related Macular Degeneration Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Age Related Macular Degeneration Drugs Market Dynamics
- 2.1 Age Related Macular Degeneration Drugs Industry Trends
- 2.2 Age Related Macular Degeneration Drugs Industry Drivers
- 2.3 Age Related Macular Degeneration Drugs Industry Opportunities and Challenges
- 2.4 Age Related Macular Degeneration Drugs Industry Restraints
3 Age Related Macular Degeneration Drugs Market by Manufacturers
- 3.1 Global Age Related Macular Degeneration Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Age Related Macular Degeneration Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Age Related Macular Degeneration Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Age Related Macular Degeneration Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Age Related Macular Degeneration Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Age Related Macular Degeneration Drugs Manufacturers, Product Type & Application
- 3.7 Global Age Related Macular Degeneration Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Age Related Macular Degeneration Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Age Related Macular Degeneration Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Age Related Macular Degeneration Drugs Tier 1, Tier 2, and Tier 3
4 Age Related Macular Degeneration Drugs Market by Type
- 4.1 Age Related Macular Degeneration Drugs Type Introduction
- 4.1.1 Eylea
- 4.1.2 Avastin
- 4.1.3 Squalamine
- 4.1.4 Conercept
- 4.1.5 Lampalizamab
- 4.1.6 Lucentis
- 4.1.7 Others
- 4.2 Global Age Related Macular Degeneration Drugs Sales by Type
- 4.2.1 Global Age Related Macular Degeneration Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Age Related Macular Degeneration Drugs Sales by Type (2021-2032)
- 4.2.3 Global Age Related Macular Degeneration Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Age Related Macular Degeneration Drugs Revenue by Type
- 4.3.1 Global Age Related Macular Degeneration Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Age Related Macular Degeneration Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Age Related Macular Degeneration Drugs Revenue Market Share by Type (2021-2032)
5 Age Related Macular Degeneration Drugs Market by Application
- 5.1 Age Related Macular Degeneration Drugs Application Introduction
- 5.1.1 50-60 Years Old
- 5.1.2 60-70 Years Old
- 5.1.3 Others
- 5.2 Global Age Related Macular Degeneration Drugs Sales by Application
- 5.2.1 Global Age Related Macular Degeneration Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Age Related Macular Degeneration Drugs Sales by Application (2021-2032)
- 5.2.3 Global Age Related Macular Degeneration Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Age Related Macular Degeneration Drugs Revenue by Application
- 5.3.1 Global Age Related Macular Degeneration Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Age Related Macular Degeneration Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Age Related Macular Degeneration Drugs Revenue Market Share by Application (2021-2032)
6 Global Age Related Macular Degeneration Drugs Sales by Region
- 6.1 Global Age Related Macular Degeneration Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Age Related Macular Degeneration Drugs Sales by Region (2021-2032)
- 6.2.1 Global Age Related Macular Degeneration Drugs Sales by Region (2021-2026)
- 6.2.2 Global Age Related Macular Degeneration Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Age Related Macular Degeneration Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Age Related Macular Degeneration Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Age Related Macular Degeneration Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Age Related Macular Degeneration Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Age Related Macular Degeneration Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Age Related Macular Degeneration Drugs Revenue by Region
- 7.1 Global Age Related Macular Degeneration Drugs Revenue by Region
- 7.1.1 Global Age Related Macular Degeneration Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Age Related Macular Degeneration Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Age Related Macular Degeneration Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Age Related Macular Degeneration Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Age Related Macular Degeneration Drugs Revenue (2021-2032)
- 7.2.2 North America Age Related Macular Degeneration Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Age Related Macular Degeneration Drugs Revenue (2021-2032)
- 7.3.2 Europe Age Related Macular Degeneration Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Age Related Macular Degeneration Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Age Related Macular Degeneration Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Age Related Macular Degeneration Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Age Related Macular Degeneration Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novartis
- 8.1.1 Novartis Company Information
- 8.1.2 Novartis Business Overview
- 8.1.3 Novartis Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novartis Age Related Macular Degeneration Drugs Product Portfolio
- 8.1.5 Novartis Recent Developments
- 8.2 Roche
- 8.2.1 Roche Company Information
- 8.2.2 Roche Business Overview
- 8.2.3 Roche Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Roche Age Related Macular Degeneration Drugs Product Portfolio
- 8.2.5 Roche Recent Developments
- 8.3 Bayer Healthcare
- 8.3.1 Bayer Healthcare Company Information
- 8.3.2 Bayer Healthcare Business Overview
- 8.3.3 Bayer Healthcare Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bayer Healthcare Age Related Macular Degeneration Drugs Product Portfolio
- 8.3.5 Bayer Healthcare Recent Developments
- 8.4 Regeneron Pharmaceuticals
- 8.4.1 Regeneron Pharmaceuticals Company Information
- 8.4.2 Regeneron Pharmaceuticals Business Overview
- 8.4.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
- 8.4.5 Regeneron Pharmaceuticals Recent Developments
- 8.5 Neurotech Pharmaceuticals
- 8.5.1 Neurotech Pharmaceuticals Company Information
- 8.5.2 Neurotech Pharmaceuticals Business Overview
- 8.5.3 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Neurotech Pharmaceuticals Age Related Macular Degeneration Drugs Product Portfolio
- 8.5.5 Neurotech Pharmaceuticals Recent Developments
- 8.6 Allergan
- 8.6.1 Allergan Company Information
- 8.6.2 Allergan Business Overview
- 8.6.3 Allergan Age Related Macular Degeneration Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Allergan Age Related Macular Degeneration Drugs Product Portfolio
- 8.6.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Age Related Macular Degeneration Drugs Value Chain Analysis
- 9.1.1 Age Related Macular Degeneration Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Age Related Macular Degeneration Drugs Production Mode & Process
- 9.2 Age Related Macular Degeneration Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Age Related Macular Degeneration Drugs Distributors
- 9.2.3 Age Related Macular Degeneration Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst